 |
- Following Merck acquisition of OncoImmune in Dec 2020
- $50M strategic investment from Merck
|
|
 |
- ONC-392: Strong clinical data as truly safe CTLA-4 directed therapy
- ONC-841:781 target CD24-Siglec 10 pathway: a novel “Do-Not-Eat” signal as well as ADCC/ADCP immune checkpoint
- ONC-782, 783 and 784: Broadly targeting all major cancers
- ONC-895: Represents a new and selective way to differentially regulate PD-L1 in tumors vs normal tissues
|
|
 |
- Management team has a proven track record of scientific innovation with broad experience and deep backgrounds in drug development, operations, manufacturing, FDA and regulatory bodies, business development and capital markets
|
|
|
